Skip to main content
. 2024 Jul 12;15:1426446. doi: 10.3389/fphar.2024.1426446

FIGURE 7.

FIGURE 7

(A) Glucose levels (n = 10 animals for non-diabetic group, n = 7 animals for diabetic control group, and n = 9 animals for RG7774 10 mg/kg daily group) and (B) Body weights (n = 10 animals for non-diabetic group, n = 7 animals for diabetic control group, and n = 9 for RG7774 10 mg/kg daily group) 6 weeks after streptozotocin (STZ) injection in nondiabetic rats and diabetic rats treated with vehicle control or RG7774 10 mg/kg daily via oral gavage for 5 weeks. (C) Levels of vitreous fluorescein (n = 16 eyes for non-diabetic group, n = 12 eyes for diabetic control group, and n = 13 eyes for RG7774 10 mg/kg daily group) 6 weeks after STZ injection and 60 min after fluorescein injection in nondiabetic rats and diabetic rats treated with vehicle control or RG7774 10 mg/kg. Levels of fluorescein were normalized to levels in plasma samples taken 1 h after fluorescein injection. Data are shown as mean ± standard error of the mean (SEM) with n = 7–10 animals per group (A,B) or 12–16 eyes per group (C). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs nondiabetic rats based on 1-way analysis of variance (ANOVA) (A,B) or 2-way ANOVA (C), followed by Newman–Keuls post hoc analysis.